Trial NCT00632827

View at ClinicalTrials.gov 
Org. Study IDs: 072518
Secondary IDs: NCI-2011-01285

Last trial update was posted on 2020-04-27

MeSH Interventions

Carmustine Cyclophosphamide Cytarabine Denileukin diftitox Doxorubicin Etoposide Gemcitabine Lenograstim Leucovorin Liposomal doxorubicin Methotrexate Vincristine Vinorelbine

MeSH Conditions

Lymphoma Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral

Other Conditions

Peripheral T-Cell Lymphoma

Stopping Reasons

Manufacturing shortage of both Diftitox and Doxil

Limitations And Caveats

Enrollment was terminated prematurely due to manufacturing shortages of Doxil and Denileukin Diftitox (Ontak). All eligible patients who received at least one dose of study regimen were included in the analyses

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID